AACR21: Bris­tol My­ers looks to build Op­di­vo's case in ear­ly can­cer with full da­ta in pre-sur­gi­cal NSCLC

Check­point in­hibitors have com­plete­ly changed the land­scape of metasta­t­ic, un­re­sectable can­cer since their in­tro­duc­tion. But one re­main­ing fron­tier is in pa­tients whose tu­mors can still be re­moved, and Bris­tol My­ers Squibb thinks it has a case to be made for PD-1 block­er Op­di­vo in that set­ting.

Bris­tol My­ers’ Op­di­vo giv­en as a neoad­ju­vant com­bi­na­tion with chemo post­ed a 24% patho­log­i­cal com­plete re­sponse (pCR) rate for pa­tients across the PD-(L)1 ex­pres­sion spec­trum with non-small cell lung can­cer com­pared with just 2.2% for chemo alone, ac­cord­ing to late break­ing Phase III da­ta from the CHECK­MATE-816 study pre­sent­ed Sat­ur­day at the vir­tu­al AACR an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER